๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

โœ Scribed by Andrew X. Zhu; Thomas A. Abrams; Rebecca Miksad; Lawrence S. Blaszkowsky; Jeffrey A. Meyerhardt; Hui Zheng; Alona Muzikansky; Jeffrey W. Clark; Eunice L. Kwak; Deborah Schrag; Kathryn R. Jors; Charles S. Fuchs; A. John Iafrate; Darrell R. Borger; David P. Ryan

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
319 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase 2 study of cetuximab in patients w
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
โœ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 131 KB

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.

Phase 2 study of erlotinib in patients w
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
โœ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti